SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Pathways

Background:

• Protein kinase activation is common in pancreatic ductal adenocarcinoma (PDAC).
• The role of kinases in ferroptosis resistance in PDAC is not well understood.
• Understanding these mechanisms is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the role of SIK1 in ferroptosis resistance in PDAC.
• To elucidate the molecular mechanisms underlying SIK1-mediated ferroptosis resistance.
• To evaluate SIK1 as a potential therapeutic target for PDAC treatment.

Main Methods:

• Kinase database screening to identify key regulators of ferroptosis resistance.
• In vitro experiments using PDAC cell lines to assess the effects of SIK1 inhibition.
• Mechanistic studies involving protein phosphorylation, interaction, and degradation assays.
• In vivo studies using organoid and patient-derived xenograft (PDX) models.
• Clinical correlation analysis of SIK1 and SLC7A11 expression in PDAC specimens.

Main Results:

• SIK1 was identified as a key regulator of ferroptosis resistance in PDAC.
• Targeting SIK1 reversed ferroptosis resistance and enhanced gemcitabine's efficacy by increasing ferroptosis sensitivity.
• SIK1 phosphorylates HDAC5, stabilizing it against degradation and leading to STAT6 deacetylation and SLC7A11 upregulation.
• SIK1 inhibition synergistically enhanced antitumor effects in preclinical models by inducing ferroptosis.
• High SIK1 expression correlated with high SLC7A11 and poor prognosis in PDAC patients.

Conclusions:

• PDAC cells resist ferroptosis through the SIK1-HDAC5-STAT6-SLC7A11 axis.
• SIK1 inhibition represents a promising therapeutic strategy to overcome drug resistance in PDAC.
• Targeting the SIK1-HDAC5 pathway offers a novel approach for PDAC treatment.